Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats

Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats

Sorafenib (SOR), an inhibitor of multiple kinases, is a classic targeted drug for advanced hepatocellular carcinoma (HCC) which often coexists with type 2 diabetes mellitus (T2DM). Dapagliflozin (DAPA), a sodium–glucose cotransporter-2 inhibitor (SGLT2i), is widely used in patients with T2DM. Notabl...

Full description

Bibliographic Details
Main Authors: Xueru He, Ying Li, Yinling Ma, Yuhao Fu, Xuejiao Xun, Yanjun Cui, Zhanjun Dong
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Molecules
Subjects:
UPLC-MS/MS
sorafenib
dapagliflozin
pharmacokinetics
drug–drug interactions
Online Access:https://www.mdpi.com/1420-3049/27/19/6190

Similar Items

Similar Items